A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
Sub-indication: CNS Cancer
Principal Investigator: Renato LaRocca, M.D.Norton Cancer Institute
Sponsor: Sumitomo Dainippon Pharma Oncology, Inc.
Email for more information: CNS-NCIResearch@nortonhealthcare.org